{
    "nctId": "NCT03712696",
    "briefTitle": "Efficacy and Safety of DIGNICAP\u2122 System",
    "officialTitle": "A Study on the Efficacy and Safety of DIGNICAP\u2122 System for Preventing Chemotherapy Induced Alopecia",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Chemotherapy-induced Alopecia",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 139,
    "primaryOutcomeMeasure": "Reduction of hair loss",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\> 18 years of age Performance status (ECOG) 0- 1\n* Documented diagnosis of stage I or II breast cancer\n* A planned course of chemotherapy in the adjuvant setting with curative intent including one of the following regimens:\n\n  * Doxorubicin 60 mg/m2 or Epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 x 4 cycles IV every 3 weeks\n  * Docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2 x 4 cycles IV every 3 weeks\n  * Paclitaxel 80 mg/m2 weekly IV x at least 12 weeks with or without IV trastuzumab\n  * Docetaxel 75-100 mg/m2 IV every 3 weeks x 4 cycles with or without trastuzumab IV weekly or every 3 weeks\n  * Targeted agents such as trastuzumab are allowed\n  * Patients receiving a regimen including both an anthracycline and a taxane (at doses reported above) are also eligible for this trial (AC/T, EC/T, TAC, etc.)\n* Plan to complete chemotherapy within 6 months\n* Willing and able to sign informed consent for protocol treatment\n* Willing to participate in study procedures including having photographs of the head before the first cycle of chemotherapy and 1 month after the last chemotherapy\n* Willing to enroll in an extension protocol for follow up for 5 years following the end of chemotherapy treatment\n* Negative pregnancy test (in fertile women).\n\nExclusion Criteria:\n\n* Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale\n* Previous chemotherapy\n* Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss\n* A history of whole brain radiation\n* Plans to use a chemotherapy regimen other than those specified in the inclusion criteria.\n* Concurrent hormone therapy with chemotherapy except LHRH analogue. Hormone therapy should be used as indicated following completion of chemotherapy\n* Underlying clinically significant liver disease including active viral hepatitis with abnormal liver function tests \\>1.5 times the upper limit of normal, including alkaline phosphatase, AST, and total bilirubin. Patients with Gilbert\u00b4s disease (elevated indirect bilirubin only) will be eligible for participation.\n* Clinically significant renal dysfunction defined as serum creatinine \\> upper limit of normal.\n* A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up\n* A history of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens\n* Participation in any other clinical investigation or exposure to other investigational agents, drugs, device or procedure that may cause hair loss Intercurrent life-threatening malignancy\n* A history of cold agglutinin disease or cryoglobulinemia.\n* Evidence of untreated or poorly controlled hyper or hypothyroidism\n* A history of silicon allergy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}